Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
120 participants
OBSERVATIONAL
2024-10-01
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The PEACH study aims to bridge these knowledge gaps by investigating how plasticizers affect human health. The study focuses on understanding how these chemicals are absorbed, distributed, and accumulated in the body across different groups of patients. The investigators are particularly interested in how plasticizers influence gut microbiota and the functionality of immune cells, as well as their effects on neurotransmitters involved in brain function.
A combination of patient data, systems biology, and laboratory models will be used to thoroughly assess the biological impacts of plasticizers. Advanced techniques such as mass spectrometry will aid in studying toxicokinetic properties, sequencing technologies will be used to examine immune effects, and radiouptake assays will be employed to explore interactions with neurotransmitter transport. This comprehensive methodology will provide new insights into the effects of both short-term and long-term exposure to plasticizers.
The PEACH study introduces innovative methods to the field, aiming to create a robust model for understanding how plasticizer compounds behave in the human body. It employs state-of-the-art techniques to assess the dynamics of these chemicals, marking a significant advancement in environmental health research.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
NCT00693550
Oral Manifestations of Aplastic Anemia
NCT00006300
Endocrine Disruptors in Saliva Released From Bruxism Splints.
NCT06088238
Day Long Prevention of Oral Malodor With a Palatal Patch (SmellX) Containing A Herbal Formula
NCT01388023
In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
NCT01405794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research questions: The PEACH study is designed to fill critical gaps in the understanding of the biological implications of plasticizer exposure. The investigators aim to analyse the pharmacokinetics of plasticizers in different patient cohorts and elucidate their bioaccumulation, distribution, and metabolism. Thereby, the interplay between plasticizer exposure and metabolism, gut microbiota composition and immune cell functionality will be explored. Furthermore, the impact of plasticizer exposure on neurotransmitter physiology will be elucidated.
Approach: The study employs a comprehensive methodology that integrates the findings from clinical cohorts, systems biology approaches, and in vitro models. Three distinct work packages will examine pharmacokinetic properties via mass spectrometry, study immunological effects through advanced sequencing technologies \& phenotypization, and investigate pharmacodynamic interactions with neurotransmitter transporters using human in-vitro assays. Longitudinal sampling from acute and chronic exposure cohorts will offer an evolving perspective on effects of plasticizer exposure.
Level of originality: The PEACH study introduces groundbreaking methodologies and scope to the investigation of plasticizer exposure. It aims to support the scientific community with first human in-vivo pharmacokinetic models for these compounds while utilizing high-throughput techniques for pharmacodynamic assessment, marking a notable advancement in the field.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transfusion-dependent thalassemia major (TDTM)
Patients suffering from homozygous transfusion-dependent Thalassemia Major.
No interventions assigned to this group
Thalassemia Minor
Patients suffering from heterozygous transfusion-independent Thalassemia Minor.
No interventions assigned to this group
Healthy controls
Healthy adult controls without any prevalent substance use (nicotine, alcohol etc.).
No interventions assigned to this group
Glioma patients
Adults with high/low-grade glioma, a tumor size \> 3cm that require resection with access to the ventricular system without ventricular hemorrhage.
No interventions assigned to this group
ICU patients
Adults with brain hemorrhage (intracranial, subdural, subarachnoidal), treated with a ventricular shunt.
No interventions assigned to this group
Patients undergoing diagnostic lumbar-puncture (plastic-naive)
Adults that receive a diagnostic lumbar puncture in an outpatient setting.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Thalassemia Intermedia/Minor:
* Inclusion: Adult, homozygous/heterozygous ß-Thalassemia Intermedia/Minor
* Exclusion: Plastic implants, chronic infectious disease, pregnancy, transfusion dependency
Healthy adults:
* Inclusion: Adult
* Exclusion: Chronic disease, plastic implants, infectious disease, pregnancy, anemia, medication-, drug-, or alcohol-abuse
Glioma patients:
* Inclusion: Adult, high/low-grade glioma, tumor larger then 3cm, resection with access to the ventricular system
* Exclusion: Large intraventricular hemorrhage, plastic implants, infectious disease
ICU patients:
* Inclusion: Adult, brain hemorrhage, external CSF drain from ventricle
* Exclusion: intraventricular hemorrhage, plastic implants, ECMO, hemodialysis, infectious disease
Patients undergoing diagnostic lumbar-puncture:
* Inclusion: Adult, diagnostic CSF sampling, outpatient setting
* Exclusion: Ventricular hemorrhage, plastic implants, infectious disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vienna
OTHER
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lukas Wisgrill
Principal Investigator, MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10.55776/KLP1811624
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
1716/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.